Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR in diabetic retinopathy extension
NCT00248131Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2005
- Primary completion
- Jul 2006
- Modality
- Peptides
01
Overview
A Phase 3 trial of octreotide in diabetic retinopathy (DR), sponsored by Novartis. Started Nov 2005; status: terminated.
02
Drugs
octreotide
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT00248131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248131.